Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb 14;140(6):2072-2075.
doi: 10.1021/jacs.8b00087. Epub 2018 Feb 6.

Scalable Access to Arylomycins via C-H Functionalization Logic

Affiliations

Scalable Access to Arylomycins via C-H Functionalization Logic

David S Peters et al. J Am Chem Soc. .

Abstract

Arylomycins are a promising class of "latent" antibacterial natural products currently in preclinical development. Access to analogues within this family has previously required a lengthy route involving multiple functional group manipulations that is costly and time-intensive on scale. This study presents a simplified route predicated on simple C-H functionalization logic that is enabled by a Cu-mediated oxidative phenol coupling that mimics the putative biosynthesis. This operationally simple macrocyclization is the largest of its kind and can be easily performed on gram scale. The application of this new route to a formal synthesis of the natural product and a collection of new analogues along with their biological evaluation is also reported.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
Contrasting retrosynthetic analyses of the arylomycin macrocycle (illustrated with natural variant arylomycin A2).
Scheme 1
Scheme 1. Synthesis of the Arylomycin Core via Oxidative Macrocyclization
Reagents and conditions: (a) 1 (1 equiv), HCl·NH2-Ala-Tyr-OMe (1 equiv), HOBt (1 equiv), EDC (1.5 equiv), Et3N (3.3 equiv), MeCN/DMF, 25 °C (72%); (b) [Cu(MeCN)4][PF6] (2 equiv), TMEDA (2 equiv), O2, MeCN, then 2 (1 equiv), 25 °C (60%). Abbreviations: HOBt = 1-hydroxybenzotriazole, EDC = N-ethyl-N′-(3-(dimethylamino)propyl)carbodiimide hydrochloride, TMEDA = N,N,N′,N′-tetramethylethylenediamine.
Scheme 2
Scheme 2. Development of Arylomycin Analogues: (A) Synthesis of Analogues via Decarboxylative Methodsa and (B) MIC Assay of Antibacterial Activity
Reagents and conditions: (a) 3 (1 equiv), AcCl (10 equiv), MeOH, 0 to 25 °C; (b) 5 (2 equiv), PyAOP (2 equiv), DIPEA (6 equiv), DMF, 50 °C (82%, 2 steps); (c) 6 (1 equiv), LiOH (10 equiv), THF/H2O, 0 to 25 °C; (d) TFA/CH2Cl2 (1:6), 0 to 25 °C (41%, 2 steps); (e) N-Boc-2-bromoethan-1-amine (4 equiv), K2CO3 (5 equiv), DMF, 50 °C; (f) LiOH (10 equiv), THF/H2O, 0 to 25 °C (69%, 2 steps); (g) TFA/CH2Cl2 (1:6), 0 to 25 °C (40%); (h) 8 (1 equiv), DIC (1.1 equiv), NHPI (1.1 equiv), CH2Cl2, 25 °C; (i) and (k) see Supporting Information for details. Abbreviations: DIPEA = N,N-diisopropylethylamine, DIC = N,N′-diisopropylcarbodiimide, NHPI = N-hydroxyphthalimide. 6 isolated as a 1:1 mixture of diastereomers at α-C of diaminobutyric acid; all assayed compounds diastereomerically pure in configuration shown (see Supporting Information for details). MRSA USA 300. MRSA COL. E. coli BAS901 (perm.).

Similar articles

Cited by

References

    1. Schimana J.; Gebhardt K.; Holtzel A.; Schmid D. G.; Sussmuth R.; Muller J.; Pukall R.; Fiedler H. P. J. Antibiot. 2002, 55, 565–70. 10.7164/antibiotics.55.565. - DOI - PubMed
    2. Kulanthaivel P.; Kreuzman A. J.; Strege M. A.; Belvo M. D.; Smitka T. A.; Clemens M.; Swartling J. R.; Minton K. L.; Zheng F.; Angleton E. L.; Mullen D.; Jungheim L. N.; Klimkowski V. J.; Nicas T. I.; Thompson R. C.; Peng S. B. J. Biol. Chem. 2004, 279, 36250–8. 10.1074/jbc.M405884200. - DOI - PubMed
    3. Paetzel M.; Goodall J. J.; Kania M.; Dalbey R. E.; Page M. G. J. Biol. Chem. 2004, 279, 30781–90. 10.1074/jbc.M401686200. - DOI - PubMed
    1. Smith P. A.; Roberts T. C.; Romesberg F. E. Chem. Biol. 2010, 17, 1223–31. 10.1016/j.chembiol.2010.09.009. - DOI - PMC - PubMed
    1. Tan Y. X.; Romesberg F. E. MedChemComm 2012, 3, 916–925. 10.1039/c2md20043k. - DOI
    1. Roberts T. C.; Schallenberger M. A.; Liu J.; Smith P. A.; Romesberg F. E. J. Med. Chem. 2011, 54, 4954–63. 10.1021/jm1016126. - DOI - PMC - PubMed
    2. Therien A. G.; Huber J. L.; Wilson K. E.; Beaulieu P.; Caron A.; Claveau D.; Deschamps K.; Donald R. G.; Galgoci A. M.; Gallant M.; Gu X.; Kevin N. J.; Lafleur J.; Leavitt P. S.; Lebeau-Jacob C.; Lee S. S.; Lin M. M.; Michels A. A.; Ogawa A. M.; Painter R. E.; Parish C. A.; Park Y. W.; Benton-Perdomo L.; Petcu M.; Phillips J. W.; Powles M. A.; Skorey K. I.; Tam J.; Tan C. M.; Young K.; Wong S.; Waddell S. T.; Miesel L. Antimicrob. Agents Chemother. 2012, 56, 4662–70. 10.1128/AAC.00726-12. - DOI - PMC - PubMed
    3. Liu J.; Smith P. A.; Steed D. B.; Romesberg F. Bioorg. Med. Chem. Lett. 2013, 23, 5654–9. 10.1016/j.bmcl.2013.08.026. - DOI - PMC - PubMed
    1. Roberts T. C.; Smith P. A.; Campbell D.; Duron S. G.; Higuchi R. I.. Broad spectrum antibiotics. U.S. Patent Application 15/358,100, Nov 21, 2016.

Publication types